Noticias y Actividades de Clarity Pharmaceuticals
Presencia
Sede: Australia
Clarity Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización CU6 (AU).
Ejecutivos
Ver el organigrama con sus 25 ejecutivos principales
Biografías más buscadas en Clarity Pharmaceuticals
- Michelle Parker, Chief Executive Officer
- Chris Roberts, Non-Executive Director
- Allison Rossiter, Independent Non-Executive Director
Recientes movimientos de ejecutivos en Clarity Pharmaceuticals
- Allison Rossiter, se ha incorporado a la empresa como Independent Non-Executive Director (noticia publicada el 17 de julio de 2026).
- Colin Biggin que ha sido Excecutive Director, pasa a ser Chief Operating Officer (noticia publicada el 12 de abril de 2026).
Crear su alerta
para seguir los movimientos de los ejecutivos en Clarity Pharmaceuticals.
Farmacia
Clarity Pharmaceuticals tiene 1.919 competidores entre los que se incluyen Sanofi (Francia), Moderna (Estados Unidos) y Eli Lilly (Estados Unidos).
Popular M&A news in Farmacia
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado el 17 de julio de 2026).
- Agenus acaba de anunciar una recaudación de fondos de 340 millones de dólares. (publicado el 17 de julio de 2026).
- GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Clarity Pharmaceuticals
- Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity’s COBRA study selected as a Top-Rated Oral Presentation at prestigious industry Annual Meeting - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity promotes Michelle Parker to CEO - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Copper-67 SAR-bisPSMA updates - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- SECuRE trial advances: No dose limiting toxicities and strong preliminary efficacy data in first multi-dose cohort - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity launches $121 million fully underwritten equity raising - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity successfully completes Placement and Institutional Entitlement Offer - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- SECuRE update: First participant treated in the last cohort of dose escalation - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- Clarity’s theranostic prostate cancer trial advances to multi-dose phase - Clarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
- View more press releases Close
Redes sociales sobre Clarity Pharmaceuticals
- Clarity Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Clarity Pharmaceuticals en LinkedIn, Twitter y YouTube
